arrow
A

Alessandra Fabi

fondazione policlinico universitario a gemelli
H指数:46
被引数:8,365

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Effect of dose-dense adjuvant chemotherapy in patients with node-positive early breast cancer according to estrogen receptor levels: an exploratory analysis of the GIM2 trial

根据雌激素受体水平,剂量密集型辅助化疗对淋巴结阳性早期乳腺癌患者的影响:GIM2试验的探索性分析

Breast
IF7.9
2026-09-290
OA
Patients’ and oncologists’ perspectives on shared decision-making and treatment communication in HR+/HER2 − advanced breast cancer: a multicountry survey

HR+/HER2−晚期乳腺癌患者和肿瘤科医师对共同决策和治疗沟通的看法:一项多国调查

2026-09-100
OA
Real-world evidence of sacituzumab govitecan in metastatic triple-negative breast cancer: an updated multicenter analysis

曲拉留单抗在转移性三阴性乳腺癌中的真实世界证据:一项更新后的多中心分析

2026-07-010
PRE
DonnaRosa Project: Exploring Informal Communication Practices Among Breast Cancer Specialists

DonnaRosa 项目:探索乳腺癌专家之间的非正式沟通实践

2025-12-140
OAAI
Lifestyle and environmental factors in women carrying BRCA pathogenic variants with and without cancer

携带BRCA致病性变异的癌症患者与非癌症患者的女性生活方式及环境因素

2025-12-010
OAAI
Digital integration of narrative medicine and patient-reported outcome measures to improve understanding of quality of life in metastatic breast cancer: the PERGIQUAL study

叙事医学与患者报告结局测量指标的数字化整合以改善对转移性乳腺癌患者生活质量的理解:PERGIQUAL研究

2025-12-010
PRE
Bisphenol A triggers adipocyte dysfunction, thereby fostering triple-negative breast cancer aggressiveness

双酚A触发脂肪细胞功能障碍,从而促进三阴性乳腺癌的侵袭性。

2025-11-270
PREAI
Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase 3 trial

新辅助曲妥珠单抗德鲁替康单药或序贯多西他赛、曲妥珠单抗和帕妥珠单抗治疗高危HER2阳性早期乳腺癌(DESTINY-Breast11):一项随机、开放标签、多中心、III期临床试验

2025-10-210
OAAI
Bone Health and Endocrine Therapy with Ovarian Function Suppression in Premenopausal Early Breast Cancer: A Real-Life Monocenter Experience with Denosumab

绝经前早期乳腺癌患者中骨健康与卵巢功能抑制内分泌治疗:一项使用Denosumab的真实世界单中心经验

2025-08-230
PRE
Safety of having a subsequent pregnancy after prior diagnosis of breast cancer during pregnancy in young BRCA carriers

年轻BRCA携带者在孕期被诊断患有乳腺癌后,再次怀孕的安全性

2025-08-130
OAAI
Cognitive effects of aromatase inhibitors in early breast cancer patients: a prospective study

芳香化酶抑制剂在早期乳腺癌患者中的认知影响:一项前瞻性研究

2025-07-290
PRE
Long term outcomes of breast primary sarcomas and malignant phyllodes tumors: 20 years observational analysis of the BEAM∗ study group. (∗the breast European association for mesenchymal tumors)

乳腺癌肉瘤和恶性叶状肿瘤的长期预后:BEAM∗研究组的20年观察性分析。(∗乳腺癌肉瘤欧洲协会)

2025-07-080
OA
Trastuzumab plus lapatinib or chemotherapy in patients with HER2-overexpressed advanced breast cancer: a randomized, phase II trial (GIM12-TYPHER)

曲妥珠单抗联合拉帕替尼或化疗在HER2过表达的晚期乳腺癌患者中的应用:一项随机、II期试验(GIM12-TYPHER)

2025-07-010
OAAI
Bisphenol A drives nuclear factor-kappa B signaling activation and enhanced motility in non-transformed breast cells

双酚A驱动核因子-kappa B信号通路的激活并增强非转化乳腺细胞的迁移能力

2025-07-010
PRE
PREDICTIVE BRCA GENETIC TESTING IN ITALIAN PATIENTS WITH BREAST CANCER: A POSITION PAPER OF ITALIAN SCIENTIFIC SOCIETIES [Italian Association of Medical Oncology(AIOM); Italian Association of Radiotherapy and Clinical Oncology (AIRO); Italian National Association of Breast Surgeons (ANISC); Italian Society of Pathological Anatomy and Diagnostic Cytology (SIAPeC-IAP); Italian Society of Surgical Oncology (SICO); Italian Society of Human Genetic (SIGU); Italian Society of General Practice (SIMG); Italian Society of Medical and Interventional Radiology (SIRM)]

意大利乳腺癌患者预测性BRCA基因检测:意大利科学学会立场文件[意大利医学肿瘤学会(AIOM);意大利放射治疗与临床肿瘤学会 (AIRO);意大利全国乳腺外科医师协会 (ANISC);意大利病理解剖学与诊断细胞学学会 (SIAPeC-IAP);意大利外科肿瘤学会 (SICO);意大利人类遗传学会 (SIGU);意大利全科医学学会 (SIMG);意大利医学与介入放射学学会 (SIRM)]

2025-06-150
PREAI